{"name":"Cerevel Therapeutics, LLC","slug":"cerevel-therapeutics-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNUEd6bmFmQWExTlVkNEhNcXFlLVEyem84bVZKT1ZxdXFlbDNuN3FhU1BzWE9hWU5Ja19PZEw3ZDJIWlV0S1NHRFBCVlJSV1NWODJ0M3Zhb2tQUWJpYUVnYk5qS05YYlZ2T2ExNjgwdmRyNkMwNndzbmpFQ1VieWp4YTRGSEFkek9xNjhrUFdWR0ctNE9UdGt1MjF2dTcxa2tQV3ZLTnJ3aWZhclNiTjRwZVBxX0g3NlVaVUFaT0NlOVlrTG1QcFFaMmx3NkFiSlVKWFJiY3FTX1RVLVg1ZHJVSFVYNU1MSS1pc01NOFE2NVZhZHhVVDUxZTVKWmU0SEVWVG9hRW10T3lZZVhLQ1kzODR2T0Z4QncyaGFyVWlNTzdzcWpMMTRUbU9kUU1xVm56VnE0cGVxNzRLQlA5aGdJYmoxbnNUQ3BmWXRJ?oc=5","date":"2026-04-07","type":"regulatory","source":"Barchart.com","summary":"Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharma, SK Biopharma - Barc","headline":"Epilepsy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Aques","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNcnZpNF8tTkEwUUUtbVA1eFpHdEhHVFVWSWh0YnlUa1F5dWxCdWNZcXJJNjFabEwwZk53M1FMOTJZUFNZRXVwd1c2blZqVWZ3UmUxc1ExOWg0M2VXNXBIbHBsOVpGQkdEbzdqYTRWbzF2al9kMXZ0QjlZRDVjMTlRR2Y2M2x1MnBtVXFnSEdLWU1uOGRfdmh2dWlMZDU1QUJLOHpmLUphRFM2RFNMRHV0SlppUWxsUHI4QlZBXzlud1dpbTlUWG5XSFM2QS00S0kyNUVhMmFVZURSbGRURTJlYW1uVkc5Q3JIYmFzd1Q1XzhRb0hxODFZYldVXzVveDVlb0J3R1ZRR1czWENsRTJYZG9MYmhwN1k?oc=5","date":"2026-01-19","type":"pipeline","source":"PR Newswire UK","summary":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBrbFY5MjJEV015dFlNOUhfUlVocG9WVmdZOThJTE5oLU0wX3lFUjdhckFMelItb05jV3JGeTBhUmlsYWE2LWZCWk5kbmF0T29BemEwZ3M3UjRxU0NWVmRsaDdvWnFOeWtKMHhoUTRWbWw1NnpT?oc=5","date":"2026-01-12","type":"deal","source":"Fierce Pharma","summary":"The top 10 biopharma M&A deals of 2025 - Fierce Pharma","headline":"The top 10 biopharma M&A deals of 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQZnB4RzJwaHMxek83RnU3emVBYzQzTkI3SHZzbk52ZW53X2E0d0xMU1FQNHZZMXU0QmY5cXc5LXJpakxrRWRNY2ZFTmp5N2hpN1NEajF2QzhwUXpuT29vYkNmM2o2OF82dUk5bWJFVXpSeGRHd3BoUTBvd3BHajF2OGNRa1RUT2IxMW14WTh0X0t3RzQzQS1JRU1n?oc=5","date":"2025-11-14","type":"pipeline","source":"Fierce Pharma","summary":"LB Pharma, Celldex hire commercial heads as launch plans ramp up - Fierce Pharma","headline":"LB Pharma, Celldex hire commercial heads as launch plans ramp up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQdVNXOXRmQ0RIVDNVdzhEV2dZZGNQYnJ6N3cxUGE2cElvLWdIYm5aVFJiVFN3N2E4NDFqQVlFblpkaEl6dmxFU3FrdXJpeEdvcFBWN3U3eTFoVVFBMF9ic3l0OWZkekl4R0R5WVJpbkpDTFVMNXpUb0FKX1RLNVFuamxvbEVoV1BON2xrbjBSQ3g3cEo4aVRIMEhsMA?oc=5","date":"2025-07-31","type":"regulatory","source":"openPR.com","summary":"Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA - openPR.com","headline":"Schizophrenia Market Size 2034: Clinical Trials, EMA, PDMA, FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOVEtXb3VZNmVWdW1OZzNrZUQ0TkRCd3U4N3ZiZUxkRGJOWllMMnQtZmdvMjB3eVNndHRhaEZBLTg0NklYODdoMGpXeG1IQmJIajcxck9peG56enV6a3ExZDM5cmVOUWRsSjNoWEdkRnlKSEpJTkxrTzlrVzhpUFNYR2pySU9QYkphSXRXX0hqSFVOYkNH?oc=5","date":"2025-02-07","type":"deal","source":"baincapital.com","summary":"Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation - baincapital.com","headline":"Bain Capital to Acquire Mitsubishi Tanabe Pharma Corporation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxNZllSd2g1blhpVWJucGRwZ2ZFMTQ2Y2FPZ0E1NHppVzU5S1I0STBWZ1ZjblFxMXBXVHVXelhXTDF3OWd1MnlPR1ExMEFhYV9rbC02OUw3UjJRM1lJV2lyVUNORFFzR3NCZWxCeUVsYXdLTVR1UzIzQ1JQdnNvdGZaYVhqMHVOYWFSNFh5M3RXWVI4NlBRX0JKY29FbldKSUVoRk9XZU1VZXJQNFlfNjFBV2dORGVOQk9VUkdoS1JuQkd2SWcwX3RlbnUtZl9rbG9NZkNScFpGZkx6RzBGNEpsbjluQmlOejU2ZGhRSXpnS3Q0WUpQWTN2MGNUTkREbTUyQXJXdGJpY1I5YjV6N2VyenFLelZ2U2RzZ0RnSjEzQWlJbXNIRFhZcHREX0hweXNO?oc=5","date":"2024-12-12","type":"pipeline","source":"GlobeNewswire","summary":"Parkinson's Disease Market is Expected to Showcase a - GlobeNewswire","headline":"Parkinson's Disease Market is Expected to Showcase a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPcEZ3akphekFNenRhNHQ4LVJmWGVoaHRmRUlBYUVwb0VRSFBlQ2REa1JobGhaRGZYNmhKdDBueEdVUVQxTkhrSnRpNGtNbDdoVk1jTHJJSnFlVkZ6T2l3RGtsanpuVm5XWFNOQ250LWNDcGRPcmlZMWd5UW1WUHo5dzhJTnhBZnEtUHBaUEtJaXA2LWstc3ZZWUQ4LUtSRUxYQ01fN0xR?oc=5","date":"2024-12-10","type":"pipeline","source":"BioSpace","summary":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline - BioSpace","headline":"7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNUjM3TERwUVpLVWJfSk1xNkhtVlhERUdMeVF1RXpZRTc5MDQtbzBBTmtjWXgzd202eDBHRGlBMGphZm13Ym1uNTdZemtVUFdScDdUdXN2dzY5R0lCUkZZeUFGNmNTbmhYVzQzY3RCX3kxaWJ2cjhXZ1Z5THZ3a3hqRGdsbUhxV2EwVHFkdTR5QjJscFVIczA4ZU9hZXZqbGJwRGw4aW1LZ1I2TnIwdzFQZHE5VTAzelE?oc=5","date":"2024-09-26","type":"trial","source":"Fierce Biotech","summary":"AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial - Fierce Biotech","headline":"AbbVie's dopamine-focused Parkinson's treatment reduces disease burden in phase 3 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxNYkJWVTlnbmlEc1pPMUlYbWVIMnY3eUhpZGJTYjdVQnh0UDZWOEthMWM0MmxMZXRvNTdaTEZ4YXJ6ZFlUWDktdk1jbzEzZF9tNU5jZnNrN3E0REhnb3p2SXVtUVg0SFV3cS1RWHpVaWgzT1FDNmRLMkpmdEZKeDlQOEZHNV85R0s1TGFpRmZYZTRiNEZHUG5TbHBJa2VidG9pMHRaSktydVVYZ0RwTV9qVU81ZWVBanJHRWplV1J3YjFnWXhf?oc=5","date":"2023-12-07","type":"pipeline","source":"Reuters","summary":"AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say - Reuters","headline":"AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPa0ZYVkV3eUNySEo3NlBpQWtFS2xtOUtCWEFRMW9QczJ3WG41SjJXVllOdnBpR3AyUXFSYVRzdy15eTFZS00zenR6TkFLQU9jVDNpREd2eDFVaE5NWTJBRThNNzJGTVZXVGctMV9mQ19oSDhKaGRlYWVUTUhDQ1locm9tUF9PRHg1ZXlwSVFld0lDbVM0bEwybGpWQmozTEJWWnc?oc=5","date":"2023-05-05","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Cerevel CEO to exit as company nears inflection point - Fierce Biotech","headline":"Chutes & Ladders—Cerevel CEO to exit as company nears inflection point","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQa2o2MEhIdWZIWnlaVGFVSTV3ZWZ2NUZvVmFsTUd3ZW9vblNlbVVYNEJDRUYtM0NWMk45T1hqUHd4Q1RYd19aaVA2dnUwREdDSmlwS0ozcEVpMm9wZVUzdFZnd2xQWlJsMjFZMkRyV3N2M0h2bDV2TnFpZmpyVkFlSGthcF9aT2JSVk51YUJMNWcwMVV5dEkxT2NQaHhNeHFBUDVIeTk4TE1idHdzU3BOZU1pbldiLUZUVmhyZHNyOEhzZi1ZV1g5ZHh6ek1LMGtlRk5UWEwwQW9VOGtCQ0xRLUhrRENjYzFVUWZheFNUOXQxQXhaeWxZeFA4a3BUQ3kwaUhB?oc=5","date":"2023-04-05","type":"trial","source":"PR Newswire","summary":"Schizophrenia Clinical Trials Pipeline Analysis: 60+ Companies are Working to Improve the Treatment Space | DelveInsight - PR Newswire","headline":"Schizophrenia Clinical Trials Pipeline Analysis: 60+ Companies are Working to Improve the Treatment Space | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}